Google News • 1/14/2026 – 1/16/2026
A new study has explored the therapeutic potential of the CRISPR-Cas3 genome-editing system. This system is noted for being a safer gene-editing tool and shows promise for the treatment of transthyretin amyloidosis. Additionally, the CRISPR-Cas3 system is capable of editing DNA on a much larger scale.
Advertisement
Stories gain Lindy status through source reputation, network consensus, and time survival.


















